Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
LEXINGTON, Mass.—Carter Todd Alfred, the Chief Scientific Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company currently valued at $283.5 million, recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. InvestingPro data shows the company maintains a "GREAT" financial health score of 3.09, with strong liquidity metrics. The sale, which took place on January 14, involved 1,191 shares at a weighted average price of $5.13 per share, totaling approximately $6,109.
The shares were sold in multiple transactions, with prices ranging from $5.05 to $5.30. Following this transaction, Alfred holds 86,436 shares of Voyager Therapeutics. The filing was signed by Scott MacDonald, acting as Attorney-in-Fact for Carter Todd Alfred.
In other recent news, Voyager Therapeutics reported $24.6 million in collaboration revenue and $38.4 million in operational expenses during their third-quarter 2024 financial report. They also highlighted a substantial cash reserve of $345.4 million, projected to fund operations into 2027 and support multiple clinical data readouts. Citi initiated a Buy rating on Voyager, emphasizing the company's strong gene therapy pipeline. In addition, Oppenheimer reiterated an Outperform rating, expressing a positive outlook based on the Phase 2a TOGETHER study of bepranemab in early Alzheimer's disease, which is seen as a positive indicator for Voyager's anti-tau monoclonal antibody VY7523. Voyager has completed enrollment for VY7523's single ascending dose trial and plans to report initial data in the first half of 2025. Furthermore, the company's tau silencing gene therapy program is on track for U.S. IND and Health Canada CTA filing in 2026. These recent developments underline Voyager's commitment to developing treatments for neurological diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.